XBiotech Inc. (XBIT)
XBIT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1626878/000117184324001382/0001171843-24-001382-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XBIT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001626878 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$24.6M |
| Operating income | -$37.5M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $200.0M |
| Total assets | $226.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $105.0M cash; operating cash flow -$10.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 30,487,731 (2026-11-12); 30,487,731 a year earlier; 30,436,964 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Whitley Penn LLP, Austin, Texas, United States | PCAOB Form AP 2026-03-15 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$4.5M | -$4.5M | $105.0M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$6.7M | -$4.5M | $109.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$5.5M | -$9.0M | $115.5M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$26.9M | -$23.0M | $125.6M | No debt tags | Needs four quarters | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | Not filed | -$6.0M | -$4.3M | $147.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$1.8M | -$6.0M | $152.9M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$10.9M | -$6.7M | $155.9M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$10.5M | -$6.5M | $172.7M | No debt tags | Needs four quarters | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2019-06-03 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-29 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-10-26 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-10-02 |
Source: SEC EDGAR submissions feed, 409 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.7% |
| 1 month | -9.3% |
| 3 months | -15.9% |
| Year to date | -18.0% |
| 1 year | -26.0% |
| From 52-week high | -27.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| BOLD | Boundless Bio Inc. | $2.41 | -3.60% | $56.9M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| FBIO | Fortress Biotech Inc. | $1.71 | -9.04% | $57.7M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier